Opendata, web and dolomites

OPTOGENERAPY SIGNED

Optogenetic Protein Therapy for Multiple Sclerosis

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 OPTOGENERAPY project word cloud

Explore the words cloud of the OPTOGENERAPY project. It provides you a very rough idea of what is the project "OPTOGENERAPY" about.

encapsulate    ifn    leader    rejection    huge    innovation    safety    release    industrial    competitiveness    polymeric    big    engineering    implanted    subcutaneously    genexplain    scientific    miniaturization    device    clear    prototype    discontinuation    subcutaneous    saving    immune    multiple    30    combining    treatment    worldwide    easily    electronic    competences    smes    membrane    powered    push    peaks    science    light    genetically    prevent    chamber    responds    meets    class    boston    replacing    proof    optoelectronics    ultrasion    scientist    prevents    embedding    proposes    biocompatibility    demands    neuromodulation    manufacturing    sclerosis    enhanced    revolutionize    sealed    optogenetics    validated    cells    barrier    least    therapies    bio    market    szlig    drug    intensive    standard    active    optogenetic    computer    losses    synthetic    micro    interferon    optogenerapy    cell    optimal    neos    porous    pull    adherence    acts    cellular    overcoming    intravenous    stability    implant    plans    moulding    efficiency    minimal    invasiveness    2014    time    validate    optical    magazine    months    offers    gene    autonomy    wireless    biomaterials    removed    penetration    listed    confinement    preclinically    implants    engineered    performance    implantation    technological    adverse   

Project "OPTOGENERAPY" data sheet

The following table provides information about the project.

Coordinator
FUNDACIO EURECAT 

Organization address
address: AVENIDA UNIVERSITAT AUTONOMA 23
city: CERDANYOLA DEL VALLES (BARCELONA)
postcode: 8290
website: www.eurecat.org/

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Spain [ES]
 Project website http://www.optogenerapy.eu
 Total cost 6˙233˙257 €
 EC max contribution 4˙777˙257 € (77%)
 Programme 1. H2020-EU.2.1.3. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Advanced materials)
 Code Call H2020-NMBP-2016-two-stage
 Funding Scheme RIA
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2020-01-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    FUNDACIO EURECAT ES (CERDANYOLA DEL VALLES (BARCELONA)) coordinator 1˙256˙557.00
2    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 951˙345.00
3    BOSTON SCIENTIFIC LIMITED IE (GALWAY) participant 805˙880.00
4    GENEXPLAIN GMBH DE (WOLFENBUTTEL) participant 386˙100.00
5    ERASMUS UNIVERSITEIT ROTTERDAM NL (ROTTERDAM) participant 322˙590.00
6    NEOS SURGERY SL ES (DONOSTIA SAN SEBASTIAN) participant 303˙375.00
7    POLITECHNIKA LODZKA PL (LODZ) participant 255˙000.00
8    TWOPTICS SYSTEMS DESIGN SL ES (BARCELONA) participant 246˙410.00
9    ULTRASION S.L. ES (CERDANYOLA DEL VALLES) participant 172˙500.00
10    ASOCIACION ESPANOLA DE NORMALIZACION ES (MADRID) participant 77˙500.00
11    EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZUERICH CH (ZUERICH) participant 0.00

Map

 Project objective

Optogenerapy proposes a new interferon-ß (IFN-ß) drug delivery system to revolutionize Multiple Sclerosis treatment.

The aim is to develop and validate a new bio-electronic cell based implant device to be implanted subcutaneously providing controlled drug release during at least 6 months. The cell confinement within a chamber sealed by a porous membrane allows the device to be easily implanted or removed. At the same time, this membrane acts to prevent immune rejection and offers long-term safety in drug release while overcoming the adverse effects of current cellular therapies. Wireless powered optogenetics – light controlling the cellular response of genetically engineered cells – is used to control the production of IFN-ß.

Replacing standard intravenous IFN-ß delivery by subcutaneous delivery prevents short and long term side effects and efficiency-losses related to drug peaks and discontinuation, while saving non-adherence costs.

It is a low-cost system enabling large scale manufacturing and reduction of time to market up to 30% compared to other cell therapies, combining: - Polymeric biomaterials with strong optical, biocompatibility and barrier requirements, to build the cell chamber and to encapsulate the optoelectronics. - Optoelectronics miniaturization, autonomy and optical performance. - Optimal cellular engineering design, enhanced by computer modelling, for stability and performance of the synthetic optogenetic gene pathway over long-term implantation. - Micro moulding enabling optoelectronics and membrane embedding for safety and minimal invasiveness.

The innovation potential is so huge that a proof-of-concept was listed by Scientist Magazine as one of the 2014’s big advances in science.

In our top-class consortium, industrial pull meets technological push, ensuring that the preclinically validated prototype obtained at the end responds to market demands.

BOSTON SCIENTIFIC, worldwide leader in neuromodulation active implants, has clear exploitation plans and high market penetration potential. 4 research intensive SMEs: TWO, GENEXPLAIN, NEOS and ULTRASION bring specific competences while increasing their own competitiveness.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "OPTOGENERAPY" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "OPTOGENERAPY" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.1.3.)

SYNAMERA (2015)

Synergies in Nanotechnologies, Materials and Production in the European Research Area

Read More  

SMARTFAN (2018)

Smart by Design and Intelligent by Architecture for turbine blade fan and structural components systems

Read More  

ReSHEALience (2018)

Rethinking coastal defence and Green-Energy Service infrastructures through enHancEd-durAbiLIty high-performance fiber reinforced cement-based materials.

Read More